Literature DB >> 32383003

Topical delivery of 5-fluorouracil-loaded carboxymethyl chitosan nanoparticles using microneedles for keloid treatment.

Juhyun Park1, Yeu-Chun Kim2.   

Abstract

Keloids are induced by skin injuries such as surgeries, skin piercings, burns, and trauma. The intra-lesional injection of 5-fluorouracil (5-FU) is a promising therapy to treat keloid. However, local 5-FU injections have caused several side effects such as pain at administration and hyperpigmentation. This study suggests a safer and more effective 5-FU delivery system. We used microneedles to treat keloid because this method has the feasibility of self-administration without pain. In this study, 5-FU-loaded carboxymethyl chitosan (CMC) nanoparticles were prepared and characterized by various analytical methods and then coated on stainless solid microneedles. The blank CMC nanoparticles caused an increase in cell viability on human normal fibroblasts to 150%. In particular, the 5-FU-loaded CMC nanoparticles showed a significant inhibitory effect on the human keloid fibroblast to 16%. The intercellular uptake of the 5-FU-loaded CMC nanoparticles was observed on both human normal and keloid fibroblasts by using a confocal microscope. In addition, it was found that the nanoparticles showed an inhibition of TGF-β1 by ELISA. For topical drug delivery, it was confirmed that the nanoparticles coated onto the microneedles were dissolved and diffused at the administration site in the porcine dorsal skin model. According to these results, the suggested microneedle-mediated drug delivery system not only inhibits the human keloid fibroblasts by delivering drugs effectively into the keloids but also has the feasibility to self-administer without pain. Therefore, this new system including 5-FU-loaded CMC nanoparticles and microneedles has the potential to treat keloid scars. Graphical abstract.

Entities:  

Keywords:  5-Fluorouracil; Carboxymethyl chitosan; Keloid; Microneedles; Transdermal drug delivery

Year:  2021        PMID: 32383003     DOI: 10.1007/s13346-020-00781-w

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  5 in total

1.  The systematic effects of chitosan on fibroblasts derived from hypertrophic scars and keloids.

Authors:  Chuan Lv; Haiying Dai; Xin Xing; Jingde Zhang
Journal:  Indian J Dermatol Venereol Leprol       Date:  2012 Jul-Aug       Impact factor: 2.545

Review 2.  Keloids: pathophysiology and management.

Authors:  David T Robles; Erin Moore; Michelle Draznin; Daniel Berg
Journal:  Dermatol Online J       Date:  2007-07-13

Review 3.  Novel Insights on Understanding of Keloid Scar: Article Review.

Authors:  Walid Mari; Sami G Alsabri; Najib Tabal; Sara Younes; Abdulamagid Sherif; Richard Simman
Journal:  J Am Coll Clin Wound Spec       Date:  2016-11-30

4.  Morphological and immunochemical differences between keloid and hypertrophic scar.

Authors:  H P Ehrlich; A Desmoulière; R F Diegelmann; I K Cohen; C C Compton; W L Garner; Y Kapanci; G Gabbiani
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 5.  New approach to the understanding of keloid: psychoneuroimmune-endocrine aspects.

Authors:  Bernardo Hochman; Felipe Contoli Isoldi; Fabianne Furtado; Lydia Masako Ferreira
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-02-10
  5 in total
  3 in total

1.  Bilayer dissolving microneedle array containing 5-fluorouracil and triamcinolone with biphasic release profile for hypertrophic scar therapy.

Authors:  Beibei Yang; Yating Dong; Yifeng Shen; Ailin Hou; Guilan Quan; Xin Pan; Chuanbin Wu
Journal:  Bioact Mater       Date:  2021-01-27

2.  Immunotherapy for type 1 diabetes mellitus by adjuvant-free Schistosoma japonicum-egg tip-loaded asymmetric microneedle patch (STAMP).

Authors:  Haoming Huang; Dian Hu; Zhuo Chen; Jiarong Xu; Rengui Xu; Yusheng Gong; Zhengming Fang; Ting Wang; Wei Chen
Journal:  J Nanobiotechnology       Date:  2022-08-13       Impact factor: 9.429

3.  The molecular mechanism of GADD153 in apoptosis of keloid fibroblasts exposed to botulinum toxin type A.

Authors:  Ming-Shiuan Nien; Wen-Pin Cheng; Jun Feng; Yong-Yan Cui
Journal:  J Cell Mol Med       Date:  2021-09-02       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.